Physician profile
Brooke Kirk
NPI 1376208702
$4,756.09
in general payments reported to CMS, 2019-2025
25 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $1,512 · 2023: $1,722 · 2024: $1,106 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $888.93 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $498.22 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $458.58 | 2022-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $406.83 | 2022-2024 | Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.40 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $368.51 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $350.26 | 2021-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $298.27 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $221.69 | 2022-2023 | Belsomra, Verquvo, Steglatro |
| Exact Sciences Corporation | $172.40 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $150.00 | 2024 | Tremfya |
| Esperion Therapeutics, INC. | $123.01 | 2021-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $62.42 | 2022-2023 | Trintellix |
| Amarin Pharma, INC. | $57.69 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $48.57 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.40 | 2025 | |
| Dexcom, INC. | $39.76 | 2024-2025 | Dexcom G6 Transmitter |
| Cardiva Medical, INC. | $34.00 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Pfizer INC. | $33.44 | 2024 | |
| Genentech USA, INC. | $26.31 | 2021 | |
| Axonics, INC. | $21.63 | 2023 | Axonics |
| Electromed, INC. | $20.76 | 2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $16.97 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.21 | 2024 | Voquezna |
| Eisai INC. | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.